AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29258261
Drug: Oligofructose (Orafti®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose (Orafti® P95) at 15 g/day
Trial: 29258261
Drug: Oligofructose (Orafti®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose (Orafti® P95) at 10 g/day
Trial: 21715514
Drug: Cholecalciferol (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (2000 IU once daily)
Trial: 18953578
Drug: Physical Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Training plus Cognitive-Behavioral Therapy (PT + CBT)
Trial: 11190013
Drug: diclofenac 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 0.1% ophthalmic solution
Trial: 10193219
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg.kg‐1
Trial: 10193219
Drug: Vecuronium 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.08 mg.kg‐1
Trial: 24927068
Drug: Topical agent
RxNorm normalized name: topical agent combination no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agent (Skinceuticals Body Tightening Concentrate) applied twice daily to one designated thigh/buttock
Trial: 24927068
Drug: Radiofrequency (RF)
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency (RF) device (Alma Accent) treatment
Trial: 24927068
Drug: Topical agent
RxNorm normalized name: topical agent combination no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agent (Skinceuticals Body Tightening Concentrate)
Trial: 22345330
Drug: Milk-based cornstarch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based cornstarch porridge fortified with 10 mg elemental iron (FeSO4), daily, during 14 weeks
Trial: 18755342
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor
Trial: 18755342
Drug: Bivalirudin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin plus a GP IIb/IIIa inhibitor
Trial: 10102851
Drug: Best supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive care (standard management and treatment for breathlessness, breathing assessments)
Trial: 568293
Drug: Paracetamol (N-acetyl-p-amino-phenol)
RxNorm normalized name: N-acetyl-p-aminophenol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (N-acetyl-p-amino-phenol)
Trial: 30183710
Drug: Internet-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based stress management program ('I'm managing my stress'), composed of four sessions based on cognitive-behavioral therapy.
Trial: 27732819
Drug: Current standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current standard of care plus ZMapp (50 mg/kg, administered every third day)
Trial: 18622147
Drug: peg‐interferon plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peg‐interferon plus ribavirin combined therapy
Trial: 16026361
Drug: Pioglitazone (30‐45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30‐45 mg/day, n = 38)
Trial: 16026361
Drug: Metformin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (750 mg/day, n = 39)
Trial: 16026361
Drug: Glimepiride (1.0‐2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1.0‐2.0 mg/day, n = 37)
Trial: 8543404
Drug: 3 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/m2 AS101 combined with carboplatin and VP-16
Trial: 19168237
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of acetylcholine (ACh)
Trial: 17571296
Drug: Preoperative intraperitoneal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative intraperitoneal local anaesthesia (50 ml 0.5 per cent lidocaine)
Trial: 17571296
Drug: Postoperative intraperitoneal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intraperitoneal local anaesthesia (50 ml 0.5 per cent lidocaine)
Trial: 17571296
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (50 ml 0.9 per cent saline)
Trial: 16135164
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg terbutaline
Trial: 16135164
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg terbutaline after withdrawal from beta(2) agonists
Trial: 7550179
Drug: Rifabutin 300
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 300 mg/day
Trial: 2029659
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (2000 IU 12 hours prior to surgery) and Vitamin C (2 g on the day of operation)
Trial: 2029659
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no vitamin E or C treatment)
Trial: 6135725
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose propranolol (22 +/- 4 mg four times daily)
Trial: 31573893
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg/Daclatasvir 60 mg
Trial: 31573893
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg/Ledipasvir 90 mg
Trial: 30942258
Drug: Miltefosine 1.3‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miltefosine 1.3‐2 mg/kg/day for 28 days
Trial: 30942258
Drug: Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimoniate (N‐MA) 20 mg SbV/kg/day for 30 days
Trial: 27194863
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CHX (0.12%) and HVE
Trial: 9302369
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for the first 6 months followed by GH administration for the next 6 months
Trial: 8287572
Drug: Suramin i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin i.v. / Melarsoprol (during treatment)
Trial: 2882736
Drug: Office-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based behavioral therapy
Trial: 28031039
Drug: Attention training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention training using novel eye‐tracking technology and gaze‐contingent training paradigms, nine weekly home‐based sessions
Trial: 28031039
Drug: Non‐gaze‐contingent age‐appropriate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐gaze‐contingent age‐appropriate videos, nine weekly home visits
Trial: 19038848
Drug: atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin (10 mg/d) for 6 weeks
Trial: 19038848
Drug: torcetrapib/atorvastatin (60/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: torcetrapib/atorvastatin (60/10 mg/d) for 6 weeks
Trial: 17503980
Drug: Sertraline (25‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (25‐200 mg/day)
Trial: 9812660
Drug: Colonic dialysis
RxNorm normalized name: colonial bent grass pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colonic dialysis therapy with Chinese herbal medicine (from third day to eighth day)
Trial: 9812660
Drug: Combined dihydroetorphine
RxNorm normalized name: Dihydroetorphine
DrugBank: Dihydroetorphine (DB01450)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined dihydroetorphine (DHE) and methadon therapy
Trial: 8588492
Drug: Periconceptional multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periconceptional multivitamin supplementation (including 0.8 mg folic acid)
Trial: 3662586
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 200 micrograms twice daily
Trial: 28892558
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg of selonsertib orally once daily for 24 weeks
Trial: 28892558
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of selonsertib orally once daily for 24 weeks
Trial: 1424176
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CPA, 50 mg once daily from Day 5 to Day 15) and ethinyl oestradiol (EE2, 30 micrograms once daily from Day 5 to Day 24 of the menstrual cycle)
Trial: 4096742
Drug: Normal-release 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-release 10 mg nifedipine soft gelatine capsule (Pidilat)
Trial: 20219584
Drug: GaAlAs laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GaAlAs laser therapy (P = 100 mW, lambda = 830 nm, Ø = 0.06 cm(2), applied in 8 sessions with intervals of 48 hours)
Trial: 17676201
Drug: Midazolam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.02 mg kg‐1) + Propofol (0.2 mg kg‐1) + Fentanyl (1 microgram kg‐1)
Trial: 17676201
Drug: Midazolam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.02 mg kg‐1)
Trial: 17676201
Drug: Midazolam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.02 mg kg‐1) + Propofol (0.2 mg kg‐1)
Trial: 17676201
Drug: Midazolam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.02 mg kg‐1) + Fentanyl (1 microgram kg‐1)
Trial: 11902739
Drug: 10 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL/kg red blood cells
Trial: 11902739
Drug: 20 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL/kg red blood cells
Trial: 2523785
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (12 units injected subcutaneously)
Trial: 414344
Drug: Floctafenine 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floctafenine 1.6 g daily
Trial: 414344
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin 4.0 g daily
Trial: 414344
Drug: Floctafenine 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floctafenine 1.6 g daily for 3-6 months
Trial: 29298622
Drug: CoQ10 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (400 mg/day)
Trial: 28879245
Drug: 8% capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% capsaicin cream
Trial: 26237980
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine + auricular pressure (treatment group)
Trial: 26237980
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (control group)
Trial: 19706240
Drug: Celecoxib (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (selective COX-2 inhibitor) for 1 week
Trial: 10717011
Drug: Etanercept (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (0.4 mg/kg subcutaneously twice weekly for up to three months)
Trial: 9113213
Drug: Alcohol rehabilitation
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol rehabilitation program treatment
Trial: 2870226
Drug: SMS 201-995,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS 201-995, 50 micrograms/h, continuous intravenous infusion
Trial: 2975549
Drug: Glibenclamide and
RxNorm normalized name: Glibenclamide and metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide and Metformin
Trial: 28475456
Drug: Oral brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral brigatinib 90 mg once daily (arm A)
Trial: 28475456
Drug: Oral brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral brigatinib 180 mg once daily with a 7-day lead-in at 90 mg (arm B)
Trial: 26145274
Drug: Taxes on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxes on low nutrient dense foods (e.g. sweetened beverages, candy, salty snacks)
Trial: 18679669
Drug: Nebicapone 200
RxNorm normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebicapone 200 mg thrice daily for 9 days with racemic warfarin 25 mg single dose on day 4
Trial: 18679669
Drug: Racemic warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic warfarin 25 mg single dose alone
Trial: 14646973
Drug: Positive anticardiolipin
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive anticardiolipin antibody (ACLA) levels in adolescents in the case group (parents with MI<55 years)
Trial: 14646973
Drug: Positive anticardiolipin
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive anticardiolipin antibody (ACLA) levels in parents of adolescents in the case group (parents with MI<55 years)
Trial: 10715297
Drug: Vancomycin/Heparin/Ciprofloxacin flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin/Heparin/Ciprofloxacin flush solution (VHC)
Trial: 10715297
Drug: Vancomycin/Heparin (VH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin/Heparin (VH)
Trial: 3982273
Drug: Caffeine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (400 mg added to decaffeinated coffee)
Trial: 29623447
Drug: Ritonavir-boosted lopinavir
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted lopinavir (LPV/r) based antiretroviral therapy (ART)
Trial: 27029920
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (vancomycin or daptomycin)
Trial: 27029920
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus 7 days of an anti‐staphylococcal β‐lactam (flucloxacillin, cloxacillin, or cefazolin)
Trial: 20351334
Drug: vinflunine 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinflunine 320 mg/m² every 21 days
Trial: 20351334
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m² every 21 days
Trial: 17273677
Drug: Digital retinographer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital retinographer injecting 2 ml fluorescein at 10%
Trial: 17273677
Drug: Conventional retinographer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional retinographer injecting 5 ml sodium fluorescein at 10%
Trial: 11896774
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin C preparation (10% ascorbic acid and 7% tetrahexyldecyl ascorbate in polysilicone gel)
Trial: 11896774
Drug: Inactive polysilicone
RxNorm normalized name: Polysilicone-15
DrugBank: Polysilicone-15 (DB11271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive polysilicone gel base (control)
Trial: 6777178
Drug: Tocainide 400
RxNorm normalized name: tocainide 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocainide 400 mg every 8 h
Trial: 6777178
Drug: Tocainide (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocainide (after 6 months treatment)
Trial: 21492237
Drug: Implant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant treatment in patients with OLP
Trial: 20497755
Drug: Etanercept (TNF-alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (TNF-alpha receptor antagonist), administered twice weekly for 44 weeks
Trial: 15751771
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg, twice daily
Trial: 9571600
Drug: Percutaneous estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous estradiol (pE2) 1.5 mg/day
Trial: 21319007
Drug: Oral estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estriol (E3) 2 mg/day
Trial: 9571600
Drug: Percutaneous estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous estradiol (pE2) 1.5 mg/day (3rd year follow-up)
Trial: 24579474
Drug: BIFICO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIFICO therapy for 4 consecutive days
Trial: 14559889
Drug: Pharmaceutical industry-sponsored
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical industry-sponsored trial
Trial: 7981178
Drug: lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin 40 mg twice daily
Trial: 7981178
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets twice daily
Trial: 6587757
Drug: Verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120 mg thrice daily)
Trial: 4570671
Drug: Propranolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (100 mg thrice daily)
Trial: 4570671
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (20 mg thrice daily)
Trial: 28267354
Drug: Body size-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body size-specific organ and effective doses calculated using the National Cancer Institute CT (NCICT) dosimetry program.
Trial: 28267354
Drug: Reference phantom-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference phantom-based dose calculation.
Trial: 28267354
Drug: Effective dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective dose calculations for body size-specific groups.
Trial: 21516735
Drug: lornoxicam (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lornoxicam (8 or 12 mg/daily) for 15 days in addition to standard treatment
Trial: 16168782
Drug: Zinc (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (70 mg) weekly for 12 months
Trial: 2486813
Drug: Essential phospholipid
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential phospholipid choline capsules (EPLC) for a six weeks period
Trial: 2486813
Drug: Vitamin B
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B complex capsules
Trial: 1007830
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg perorally
Trial: 1007830
Drug: Atropine sulphate
RxNorm normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulphate infusion
Trial: 28790141
Drug: Amoxicillin-clavulanate (40/5.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (40/5.7 mg/kg per day)
Trial: 25872631
Drug: Mouthwash containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash containing high-molecular-weight component of cranberry (3 mg/ml)
Trial: 21641580
Drug: Internet guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet guided self-help treatment programme based on CBT for 6 months with a 6-month follow-up
Trial: 19799568
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment in non-VA EDs
Trial: 19799568
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment in VA EDs
Trial: 17038141
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 mg daily in three divided doses for 3 days before cardioversion and 1 week after
Trial: 17038141
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 mg daily
Trial: 17038141
Drug: Usual medication
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual medication (Control)
Trial: 9294380
Drug: Systemic behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic behavior family therapy (SBFT)
Trial: 9294380
Drug: Individual nondirective
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual nondirective supportive therapy (NST)
Trial: 8095622
Drug: SPf66 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf66 vaccine (n = 738)
Trial: 3527555
Drug: 2 X
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 X 500 mg acetylsalicylic acid and 3 X 75 mg dipyridamole per day (treated group)